These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11859937)

  • 1. Does antisense make sense in dermatology?
    van Erp PE; Wingens M
    Acta Derm Venereol; 2001; 81(6):385-91. PubMed ID: 11859937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence-specific inhibition of gene expression in intact human skin by epicutaneous application of chimeric antisense oligodeoxynucleotides.
    Wingens M; Pfundt R; van Vlijmen-Willems IM; van Hooijdonk CA; van Erp PE; Schalkwijk J
    Lab Invest; 1999 Nov; 79(11):1415-24. PubMed ID: 10576212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides: the state of the art.
    Aboul-Fadl T
    Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic potential of antisense oligonucleotides.
    Sharma HW; Narayanan R
    Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic oligonucleotides: the development of antisense therapeutics.
    Monteith DK; Levin AA
    Toxicol Pathol; 1999; 27(1):8-13. PubMed ID: 10367666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
    Cucco C; Calabretta B
    Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.
    Bennett CF; Swayze EE
    Annu Rev Pharmacol Toxicol; 2010; 50():259-93. PubMed ID: 20055705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligodeoxynucleotides.
    Stein CA; Narayanan R
    Curr Opin Oncol; 1994 Nov; 6(6):587-94. PubMed ID: 7827170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
    Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective intracellular delivery of oligonucleotides in order to make sense of antisense.
    Shi F; Hoekstra D
    J Control Release; 2004 Jun; 97(2):189-209. PubMed ID: 15196747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotides in cutaneous therapy.
    Wraight CJ; White PJ
    Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?
    Lavigne C; Yelle J; Sauve G; Thierry AR
    AAPS PharmSci; 2002; 4(2):E9. PubMed ID: 12102618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue.
    Golden T; Dean NM; Honkanen RE
    Microcirculation; 2002 Jan; 9(1):51-64. PubMed ID: 11896559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of intercellular adhesion molecule-1 protein expression by antisense oligonucleotides is neuroprotective after transient middle cerebral artery occlusion in rat.
    Vemuganti R; Dempsey RJ; Bowen KK
    Stroke; 2004 Jan; 35(1):179-84. PubMed ID: 14657453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
    Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE
    Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials of a new class of therapeutic agents: antisense oligonucleotides.
    Galderisi U; Cipollaro M; Cascino A
    Expert Opin Emerg Drugs; 2001 Apr; 6(1):69-79. PubMed ID: 15989497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene inhibition using antisense oligodeoxynucleotides.
    Wagner RW
    Nature; 1994 Nov; 372(6504):333-5. PubMed ID: 7969490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.